When was NanoPass Technologies founded?

NanoPass Technologies was founded in 2000.

Where is NanoPass Technologies located?

NanoPass Technologies is headquartered in Ness Ziona, Israel.

How many employees does NanoPass Technologies have?

As of Apr 30, 2026, the latest employee count at NanoPass Technologies is 20.

Is NanoPass Technologies a funded company?

NanoPass Technologies is a funded company, having raised a total of $14.9M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of NanoPass Technologies?

NanoPass Technologies' latest funding was a $***** Series C round on Jul 15, 2024, with participation from 1 investor.

Where does NanoPass Technologies rank among its competitors?

NanoPass Technologies ranks 22nd amongst 74 active competitors, of which 29 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Vaxxas, which secured $31.9M in Aug, 2025.

Who are the top competitors of NanoPass Technologies?

NanoPass Technologies' top competitors include Vaxxas, scPharmaceuticals and BioSapien. Among them, Vaxxas secured the most recent funding round in August, 2025.

NanoPass Technologies - 2026 Company Profile, Funding & Competitors

Company Details

NanoPass Technologies develops intradermal delivery solutions for vaccines and immunotherapies. They have developed, MicronJet needle, a single use microneedles-based device for intradermal delivery. It can be used with any standard syringe to painlessly deliver any liquid substance directly into the skin. The MicronJet can be used with any standard syringe to inject drugs, proteins and vaccines approved for that delivery route.

Key Metrics

Founded Year

2000

Location

Ness Ziona, Israel

Stage

Series C

Total Funding

$14.9M in 5 rounds

Latest Funding Round

Series C, Jul 15, 2024, $*****

Investors

Israel HealthCare Ventures & 7 more

Ranked

22^nd among 74 active competitors

Employee Count

20 as on Apr 30, 2026

Similar Companies

Vaxxas & 95 more

View NanoPass Technologies' full profile

NanoPass Technologies has raised a total funding of $14.9M over 5 rounds. Its latest funding round was a Series C round on Jul 15, 2024 for $*****. 1 investor participated in its latest round. NanoPass Technologies has 8 institutional investors.

Here is the list of recent funding rounds of NanoPass Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2024	8880667	Series C	9062606	8386040	4875128	1856382
Apr 25, 2016	8764996	Series C	6877923	5712816	9672106	2628244
Jul 30, 2012	6253856	Series B	1302009	5627668	Israel HealthCare Ventures	6309033

Access funding benchmarks and valuations. Sign up today!

View details of NanoPass Technologies's funding rounds and investors

NanoPass Technologies' employee count trend

NanoPass Technologies has 20 employees as of Apr 26. Here is NanoPass Technologies's employee count trend over the years:

Employee count trend for NanoPass Technologies

Uncover NanoPass Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NanoPass Technologies include Vaxxas, scPharmaceuticals and BioSapien. Here is the list of Top 10 competitors of NanoPass Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	One Ventures, UniQuest & 12 others	65/100
2nd	scPharmaceuticals 2013, Lexington (United States), Acquired	Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure	$78.7M	Orbimed, Sun Pharma & 4 others	60/100
3rd	BioSapien 2018, New York City (United States), Seed	Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents	$10.6M	JPIN, Global Ventures & 13 others	58/100
4th	Starton 2017, New York City (United States), Seed	Developer of drug delivery solution and drugs for treating oncology	$9.29M	LOVE Pharma, Goldfingr	53/100
5th	Scilex Holding 2019, Palo Alto (United States), Public	Developer of non-opioid therapies for acute and chronic pain	-	Frazier Life Sciences	52/100
6th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	50/100
7th	Valeritas 2003, Bridgewater (United States), Acquired	Developer of wearable insulin patch pumps for insulin delivery through the skin	$231M	Welsh, Carson, Anderson & Stowe, Abingworth ... & 12 others	48/100
8th	AFYX Therapeutics 2013, Copenhagen (Denmark), Series A	Developer of drug patches for the treatment of mucosal diseases	$33.3M	Sofinnova Investments, Nordic Venture & 6 others	47/100
9th	Medherant 2015, Coventry (United Kingdom), Series A	Transdermal drug delivery patches	$13.5M	Mercia, Limpet Pension Fund & 40 others	47/100
10th	CeQur 2008, Horw (Switzerland), Series D	Developer of wearable insulin delivery patch	$392M	Endeavour Vision, Schroders & 7 others	45/100
22nd	NanoPass Technologies 2000, Ness Ziona (Israel), Series C	Microneedles-based device for intradermal delivery	$14.9M	Viola Partners, WFD Ventures & 6 others	37/100